February 10, 2021, 11:00AM (EST) presented by Matthew Hardwick, PhD, President/CEO, ResInnova Laboratories
This digital lab is offered at no cost to individual and corporate members of AATCC and at a 70 % discount (USD 45) for nonmembers. Corporate members must contact Kim Nicholson to register offline.
AATCC is pleased to announce the PPE Digital Series will continue with a fifth presentation focusing on efficacy testing of antimicrobial personal protective equipment.
PPE comes in many forms: gloves, masks, face shields, goggles, gowns, etc. The COVID-19 pandemic has caused worldwide shortages in PPE and forced a reimagining of PPE. From disinfecting and reuse to incorporation of antimicrobial agents, PPE is changing. How effective will these changes be? We will have to lean heavily on current standard test methods, as well as developing new ones.
During this presentation, we will discuss what we mean by “antimicrobial”. We will also go over current standard test methods for antimicrobial products and their positives and negatives. Finally, we will end by discussing where the antimicrobial testing field needs to go in order to meet the needs of this ever-evolving industry.
About the Speaker
Dr. Hardwick is a thought leader in the field of infection prevention in the healthcare environment of care and is an expert in antimicrobial surface technologies. He has 20 years of academic research experience, at Georgetown University where he completed his PhD in Cell Biology, and at Johns Hopkins University, where he completed 2 postdoctoral fellowships, one in the Bloomberg School of Public Health and the second in the James Buchanan Brady Urological Institute. Dr. Hardwick’s last academic appointment was with the MedStar Health Research Institute where he worked on numerous research initiatives including the use of antimicrobial surfaces in clinical healthcare environments. He is widely published, including several articles on the use of antimicrobials in clinical environments and the role of microbial surface contamination on infection rates in clinical settings.